TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10100554

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) 3 g/m2
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) 4 g/m2
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Prior chemotherapy regimen (1 regimen)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Prior chemotherapy regimen (>=2 regimens)
Number of subjects: 66
Study: 8947399

Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament deficiency
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hamstring tendons-ligament augmentation device anterior cruciate ligament reconstructions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone anterior cruciate ligament reconstructions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (uninjured subjects)
Number of subjects: 32
Study: 1768562

Group type: EXPERIMENTAL
Intervention: Continuous infusion of indocyanine green (ICG) at 1.0 mg min‐1 for 150 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous propranolol (10 mg in 10 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Three 1-min infusions of ICG (0.5 mg kg‐1) administered at corresponding times of the day
Number of subjects: 6
Study: 7091024

Group type: EXPERIMENTAL
Intervention: 20% protein (HP) evening meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate + 0.4% tryptophan (TRP) evening meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate evening meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate + TRP evening meal
Number of subjects: 8
Study: 31187279

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) - 30 min at 60% VO2max
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) - 30 min, 6 exercises, 3×10-repetition maximum
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (Seated Rest)
Number of subjects: 11
Study: 27605086

Group type: EXPERIMENTAL
Intervention: Low dose of beta-carotene and vitamin C supplements
Number of subjects: 23
Study: 25908099

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by intravenous bolus injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study: 23380230

Group type: EXPERIMENTAL
Intervention: PBSC + HA
Number of subjects: 50

Group type: COMPARATOR
Intervention: HA
Number of subjects: 50
Study: 21944903

Group type: EXPERIMENTAL
Intervention: isoflurane (ISF) anesthesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: sevoflurane (SVF) anesthesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: propofol (PF) anesthesia
Number of subjects: 45
Study: 19176949

Group type: EXPERIMENTAL
Intervention: Antibiotic lock solution of gentamicin (4 mg/ml) heparin (G group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Heparin alone (H group)
Number of subjects: 140
Study: 17573390

Group type: EXPERIMENTAL
Intervention: Muscle relaxant (rocuronium)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No muscle relaxant
Number of subjects: 300
Study: 15673992

Group type: EXPERIMENTAL
Intervention: n-of-1 trials
Number of subjects: 0
Study: 11493411

Group type: EXPERIMENTAL
Intervention: Atovaquone (1,000 mg) and proguanil hydrochloride (400 mg) daily for 3 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Chloroquine (1,500 mg over 3 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pyrimethamine (75 mg) and sulfadoxine (1,500 mg) as a single dose
Number of subjects: 43
Study: 9715425

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg) plus amoxycillin (500 mg) twice daily for 2 weeks (LA-60 group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) plus amoxycillin (500 mg twice daily for 2 weeks (LA-30 group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily for 6 or 8 weeks (LPZ group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Localized-type colonization
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Whole-type colonization
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Fundic mucosal atrophy
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Scanty mucosal atrophy
Number of subjects: 76
Study: 7785629

Group type: EXPERIMENTAL
Intervention: Upright lateral chest radiograph
Number of subjects: 100

Group type: COMPARATOR
Intervention: Upright posteroanterior chest radiograph
Number of subjects: 100
Study: 2375945

Group type: EXPERIMENTAL
Intervention: Caffeine, 10 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 385096

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (500 mg b.d.) for 7 days before operation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31915996

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin-warfarin (enox-warfarin)
Number of subjects: 2199
Study: 31670578

Group type: EXPERIMENTAL
Intervention: ZTE-MRI
Number of subjects: 20

Group type: COMPARATOR
Intervention: CBCT
Number of subjects: 20
Study: 28823681

Group type: EXPERIMENTAL
Intervention: Screening navigation program with personalized contact and phone navigation
Number of subjects: 14556

Group type: COMPARATOR
Intervention: Usual postal reminders for FOBT screening
Number of subjects: 14556
Study: 25819354

Group type: EXPERIMENTAL
Intervention: ossein-hydroxyapatite complex (OHC) 1,660 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: calcium carbonate (CC) 1,200 mg/day
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ossein-hydroxyapatite complex (OHC)
Number of subjects: 74

Group type: COMPARATOR
Intervention: calcium carbonate (CC)
Number of subjects: 74
Study: 24786946

Group type: EXPERIMENTAL
Intervention: Build Better Bones With Exercise (B3E) intervention including exercise and behavioral counseling, delivered by a physical therapist in 6 home visits over 8 months, and monthly calls; participants are to exercise ≥3 times weekly.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Attentional control group receiving equal attention.
Number of subjects: 160
Study: 21298494

Group type: EXPERIMENTAL
Intervention: Epirubicin and paclitaxel (ET)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Epirubicin, paclitaxel, and capecitabine (TEX)
Number of subjects: 287
Study: 19385964

Group type: EXPERIMENTAL
Intervention: Decision Aids for Mode of next Delivery
Number of subjects: 30
Study: 17565838

Group type: EXPERIMENTAL
Intervention: In situ coronary venous arterialization (ICVA) during CABG
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional CABG only (control group)
Number of subjects: 64
Study: 15382799

Group type: EXPERIMENTAL
Intervention: Swallowing intervention
Number of subjects: 79
Study: 12903226

Group type: EXPERIMENTAL
Intervention: Reduced-intervention nursing caregiving environment (RINCE)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control bed (standard RW with Plexiglas hood)
Number of subjects: 10
Study: 10386528

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8600188

Group type: COMPARATOR
Intervention: Sorbitol gum (9.0 g/day)
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: 100% xylitol pellet gum
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Xylitol-sorbitol mixtures
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Sucrose gum
Number of subjects: 1277
Study: 2469708

Group type: EXPERIMENTAL
Intervention: cetirizine, 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 1096218

Group type: EXPERIMENTAL
Intervention: Haloperidol (9 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clozapine (225 mg/day)
Number of subjects: 8
Study: 31049747

Group type: EXPERIMENTAL
Intervention: New simple risk score (Chen score)
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Classical Mehran or ACEF risk score
Number of subjects: 1157
Study: 28443283

Group type: EXPERIMENTAL
Intervention: Subclavian dialysis catheters
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Internal jugular dialysis catheters
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Femoral dialysis catheters
Number of subjects: 1016

Group type: COMPARATOR
Intervention: All catheter locations
Number of subjects: 1016
Study: 26303014

Group type: EXPERIMENTAL
Intervention: Short course radiotherapy (RT) alone (4Gy/#/day for 5 days)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Short course concurrent palliative chemotherapy (cisplatin at 6mg/m2/day IV bolus for 5 days) plus radiotherapy (RT as arm A)
Number of subjects: 111
Study: 23442280

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 21504334

Group type: EXPERIMENTAL
Intervention: Sitagliptin administration alone or with a concomitant drug
Number of subjects: 0
Study: 18718725

Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Number of subjects: 78

Group type: COMPARATOR
Intervention: SEQ
Number of subjects: 78
Study: 16562630

Group type: EXPERIMENTAL
Intervention: Constant stimulation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Randomized frequency (mean 40 Hz)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Randomized current amplitude
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Randomized pulsewidth (mean 250 micros)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All modes of stimulation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stochastic modulation of stimulation parameters
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Maximum force measurements
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10-min rest period between stimulation trials
Number of subjects: 7
Study: 15050083

Group type: EXPERIMENTAL
Intervention: Harm Reduction Group (HRG) - 12-session intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard Care (SC) - 2 hours of counseling per month and a single-session risk reduction intervention
Number of subjects: 220
Study: 11770479

Group type: EXPERIMENTAL
Intervention: Self‐Regulatory Prevention and Relationship Enhancement Program (Self‐PREP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 83
Study: 9250098

Group type: EXPERIMENTAL
Intervention: Endurance training for 5 weeks (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 44
Study: 8186781

Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil-midazolam anesthesia
Number of subjects: 65

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 65
Study: 2660754

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 gr. IM daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tobramycin (100 mgr. IM q 12 h for 7 days)
Number of subjects: 0
Study: 30953731

Group type: EXPERIMENTAL
Intervention: TeachTown: Basics
Number of subjects: 154

Group type: COMPARATOR
Intervention: Treatment as usual (waitlist control)
Number of subjects: 154
Study: 31547752

Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 28679400

Group type: EXPERIMENTAL
Intervention: Activity coaching system alongside a home-based exercise program
Number of subjects: 110

Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 110
Study: 25348833

Group type: EXPERIMENTAL
Intervention: Measured setting formulas for RMV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measured setting formulas for BV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formulas for RMV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formulas for BV
Number of subjects: 0
Study: 23442371

Group type: EXPERIMENTAL
Intervention: C1q‐APN
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: C1q‐APN/C1q ratio
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: C1q‐APN/Total‐APN ratio
Number of subjects: 117
Study: 20936499

Group type: EXPERIMENTAL
Intervention: High Youth and Mother group
Number of subjects: 938

Group type: COMPARATOR
Intervention: Low Youth/High Mother group
Number of subjects: 938
Study: 19749496

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Other statins (Simvastatin 40 mg/day, Pravastatin 40 mg/day)
Number of subjects: 40
Study: 16802360

Group type: EXPERIMENTAL
Intervention: Calcium (1,000 mg) and vitamin D (400 IU) supplementation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo and vitamin D (400 IU)
Number of subjects: 198
Study: 14627926

Group type: EXPERIMENTAL
Intervention: DeLorme technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oxford technique
Number of subjects: 50
Study: 10783648

Group type: EXPERIMENTAL
Intervention: Methacholine 0.33% (verum)
Number of subjects: 56

Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 56
Study: 9305226

Group type: EXPERIMENTAL
Intervention: Antihistamine-treated group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Immunotherapy group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Nonatopic group
Number of subjects: 99
Study: 8349365

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 10
Study: 3303976

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum; two individual consultations
Number of subjects: 334

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 334
Study: 29307660

Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/day for 12 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 12 weeks)
Number of subjects: 88
Study: 29092731

Group type: EXPERIMENTAL
Intervention: Single CER intact capsule (30 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single CER capsule contents sprinkled over applesauce (15 mL)
Number of subjects: 32
Study: 24136051

Group type: EXPERIMENTAL
Intervention: Zero-profile implant
Number of subjects: 46

Group type: COMPARATOR
Intervention: Anterior plate and cage (control group)
Number of subjects: 46
Study: 23000961

Group type: EXPERIMENTAL
Intervention: lipo-prostaglandin E1 (lipo-PGE1)
Number of subjects: 286

Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 286
Study: 21939867

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 355

Group type: COMPARATOR
Intervention: Structured brief advice
Number of subjects: 355
Study: 19100931

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.3 mg kg(‐1) IV)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Succinylcholine (1 mg kg(‐1) IV)
Number of subjects: 13
Study: 16785771

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy (PCT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavior therapy (CBT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 12695418

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NG‐monomethyl‐L‐arginine (nitric oxide synthase inhibitor)
Number of subjects: 20
Study: 11120730

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham manipulation (control)
Number of subjects: 7
Study: 8925581

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Amiodarone (nonischemic etiology)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Amiodarone (ischemic group)
Number of subjects: 674
Study: 1514723

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (3 mL, 268 mmol/L, pH 6.4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mg in 3 mL saline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulized normal saline (3 mL)
Number of subjects: 10
Study: 6653081

Group type: EXPERIMENTAL
Intervention: Orientation statement at the time the appointment was made
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orientation statement plus phone prompt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone prompt only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31235380

Group type: EXPERIMENTAL
Intervention: Intervention studies (3‐6 months)
Number of subjects: 143
Study: 29699885

Group type: EXPERIMENTAL
Intervention: CKD registry (285 patients)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Usual-care registry (461 patients)
Number of subjects: 746
Study: 26720847

Group type: EXPERIMENTAL
Intervention: 70 IU/kg intravenous unfractionated heparin (UFH) bolus
Number of subjects: 72

Group type: COMPARATOR
Intervention: In-vitro UFH spiking
Number of subjects: 72
Study: 24467802

Group type: EXPERIMENTAL
Intervention: Mindfulness training, e-coaching, lunch walking routes, and fruit (intervention group)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Control group received information on existing lifestyle behavior-related facilities (control group)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Mindfulness training (intervention group)
Number of subjects: 257
Study: 23377601

Group type: EXPERIMENTAL
Intervention: Dental health program with mothers' involvement (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brochures providing knowledge related to dental health (Control group, n=24)
Number of subjects: 50
Study: 20091486

Group type: EXPERIMENTAL
Intervention: Low sodium diet for 6 weeks
Number of subjects: 171

Group type: COMPARATOR
Intervention: Normal sodium intake (control group)
Number of subjects: 171
Study: 17384847

Group type: EXPERIMENTAL
Intervention: G1 Prime & Bond 2.1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: G2 Clearfil SE Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: G3 One Up Bond F
Number of subjects: 30
Study: 15943219

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11865170

Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg tid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (less severe hyperemesis, no steroid therapy)
Number of subjects: 30
Study: 10199874

Group type: EXPERIMENTAL
Intervention: L-arginine (6.7 g/min for 45 minutes)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DIP (intravenous dipyridamole)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve
Number of subjects: 25
Study: 8786246

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (150 mg twice daily) - Neoral
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cyclosporine A (150 mg twice daily) - Sandimmune
Number of subjects: 37

Group type: COMPARATOR
Intervention: Crossover analysis - Neoral vs Sandimmune
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 37
Study: 2083807

Group type: EXPERIMENTAL
Intervention: 6 French catheter
Number of subjects: 60

Group type: COMPARATOR
Intervention: 8 French catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 6996935

Group type: EXPERIMENTAL
Intervention: guanabenz (mean dose 24 mg daily)
Number of subjects: 29
Study: 31419023

Group type: EXPERIMENTAL
Intervention: Structured ostomy care training (oral and practical training, question and answer session, and an ostomy information booklet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine ostomy care (control group)
Number of subjects: 60
Study: 27749608

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (sham points)
Number of subjects: 69
Study: 26775477

Group type: EXPERIMENTAL
Intervention: Blood activating wind dissipating acupuncture (BAWDA) for 6 weeks (30 sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood activating wind dissipating acupuncture (BAWDA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (lifestyle intervention only)
Number of subjects: 60
Study: 23942276

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE) intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Social support group intervention
Number of subjects: 67
Study: 20352383

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Classic approach (CLASS)
Number of subjects: 120
Study: 19577150

Group type: EXPERIMENTAL
Intervention: 1-phase treatment with bionator
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: 2-phase treatment with headgear/biteplane
Number of subjects: 260

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 260
Study: 18046226

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of high-dose triamcinolone acetonide (20-25 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravitreal injection of dexamethasone (500 mug)
Number of subjects: 39
Study: 15501952

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 i.v. day 1) and capecitabine (1000 mg/m2 orally twice daily days 2‐15) for four cycles (Dose A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m2 i.v. day 1) and capecitabine (937.5 mg/m2 orally twice daily days 2‐15) for four cycles (Dose B)
Number of subjects: 30
Study: 11384089

Group type: EXPERIMENTAL
Intervention: Capecitabine as first-line treatment for metastatic breast cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose CMF (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine in paclitaxel-refractory patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine in anthracycline-refractory patients
Number of subjects: 0
Study: 9021428

Group type: EXPERIMENTAL
Intervention: Regimen A (450 mg propafenone)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Regimen B (600 mg propafenone)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: COMPARATOR
Intervention: Regimen A vs Placebo
Number of subjects: 105

Group type: COMPARATOR
Intervention: Regimen B vs Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Regimen A vs Regimen B
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mean ventricular rate reduction
Number of subjects: 105